- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Ted Okon: FTC Should Set Up Guardrails to Protect Americans From PBM Practices
As part of the investigation into pharmacy benefit managers (PBMs), the Federal Trade Commission (FTC) should delve into how PBMs are impacting and fueling drug prices and set up guardrails to protect Americans, said Ted Okon, MBA, executive director, Community Oncology Alliance.
As part of the investigation into pharmacy benefit managers (PBMs), the Federal Trade Commission (FTC) should delve into how PBMs are impacting and fueling drug prices and set up guardrails to protect Americans, said Ted Okon, MBA, executive director, Community Oncology Alliance.
Transcript
What are your hopes for the FTC investigation into PBM practices?
I think it's really [ground]breaking to have the FTC look at PBMs and the abuses that PBMs basically foist on society. What I hope is that the [FTC] really delves into what's happening with PBMs, how they are impacting and fueling drug prices, how they are adversely impacting care, especially for cancer patients, and ideally, I'd like to see the FTC break up the PBMs and the insurers.
It's a real problem when you have the top 3 PBMs literally control 80% of the prescription drug market. Add 3 more on to that, and they control 96%. And it gets even worse when you realize that those top 3 PBMs basically are owned by or own the number 1, 3, and 4 insurers.
So, I think that at the very least, the FTC has to put in place guardrails that protect Americans from PBM abuses. But ideally, I'd like to see them break up the PBMs and the insurers. It never should have been the case that we see the consolidation in the PBM market and the consolidation between PBMs and insurers.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Facilitators of and Barriers to Medicaid Investment in Electronic Consultation Services
March 5th 2025In this qualitative investigation, leaders of Medicaid managed care plans were interviewed to identify facilitators of and barriers to electronic consultation for specialty care delivery.
Read More
More than 5 years after the American Society of Clinical Oncology warned of emerging disparities in precision medicine, efforts by community practices to embrace technology, form partnerships, and use data show how patients can gain access to personalized approaches. But challenges remain, especially for those covered by Medicaid.
Read More
